Key Takeaways CorMedix launched DefenCath in 2024, generating $78.8M in H1 2025 revenues and raising guidance.CRMD acquired Melinta for $300M, adding seven marketed therapies and diversifying beyond DefenCath.MIRM's Livmarli posted $161.4M H1 2025 sales, but revenue reliance and competition pose key risks.CorMedix (CRMD) and Mirum Pharmaceuticals (MIRM) are pursuing treatments for underserved medical conditions where existing therapies are limited or nonexistent. Both companies are carving out niches in are ...

Key Takeaways CorMedix acquired Melinta for $300M, adding seven marketed therapies to its portfolio.The deal boosts 2025 revenue outlook to $325-$350M, with EPS accretion expected in 2026.Rezzayo offers near-term growth and is in phase III testing for expanded fungal infection use.CorMedix (CRMD) has taken a major step toward diversifying its revenue base and reducing reliance on a single product with the recent $300 million acquisition of Melinta Therapeutics. The move significantly expands the company’s m ...